HD Hyundai Co., Ltd. (KRX:267250)
South Korea · Delayed Price · Currency is KRW | Market Cap | 9.07T |
| Revenue (ttm) | 68.34T |
| Net Income (ttm) | 525.03B |
| Shares Out | 70.67M |
| EPS (ttm) | 7,429.46 |
| PE Ratio | 17.27 |
| Forward PE | 8.60 |
| Dividend | 3,600.00 (2.52%) |
| Ex-Dividend Date | Jun 27, 2025 |
| Volume | 495,980 |
| Average Volume | 276,554 |
| Open | 140,600 |
| Previous Close | 142,600 |
| Day's Range | 128,300 - 140,700 |
| 52-Week Range | 66,300 - 152,700 |
| Beta | 0.69 |
| RSI | 43.99 |
| Earnings Date | Jul 29, 2025 |
About CTI BioPharma
HD Hyundai Co., Ltd., through its subsidiaries, engages in oil refining business in Korea and internationally. It operates through Shipbuilding and Offshore, Oil Refining, Electrical Electronics, Construction Equipment, Ship Maintenance Service, and Others segments. The Shipbuilding and Offshore segment builds merchant ships, vessels, and industrial plants; manufactures and installs offshore oil and gas fields; manufactures, sells, and installs solar power modules, inverters, and ESS related to renewable energy; and produces ship's propulsion/g... [Read more]
Financial Performance
In 2024, HD Hyundai's revenue was 67.77 trillion, an increase of 10.49% compared to the previous year's 61.33 trillion. Earnings were 509.02 billion, an increase of 92.46%.
Financial StatementsNews
Palantir CEO Alex Karp Meets Hyundai Vice Chair to Enhance AI Shipyard, Defense Collaboration Amid Trump's Call for US Shipbuilding Revival
Earlier this month, top executives from South Korea’s shipbuilding conglomerate Hyundai Heavy Industries Group and Palantir Technologies (NASDAQ: PLTR) met to push forward AI-driven shipyard innovati...